From: ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
Characteristics | Number of patients (n = 20) |
---|---|
Age(years) | |
 <50 | 8 (40%) |
 ≥ 50 | 12 (60%) |
Gender | |
 Male | 12 (60%) |
 Female | 8 (40%) |
WHO grade | |
 II | 3 (15%) |
 III | 9 (45%) |
 IV | 8 (40%) |
Tumor size | |
 <4 cm | 11 (55%) |
 ≥ 4 cm | 9 (45%) |
Primary/Recurrent | |
 Primary | 17 (85%) |
 Recurrent | 3 (15%) |
IDH1 state | |
 IDH1(−) | 11 (55%) |
 IDH1(+) | 9 (45%) |